Prostatype Genomics AB (PROGEN) Stock Statistics & Valuation Metrics

Prostatype Genomics AB has a market cap or net worth of kr41.23M. The enterprise value is kr31.31M.

Prostatype Genomics AB has 33,523,850 shares outstanding. The number of shares has decreased by -2.65% in one year.

Prostatype Genomics AB’s return on equity (ROE) is -1.23 and return on invested capital (ROIC) is -122.06%.

The current PE Ratio of Prostatype Genomics AB is -0.81. Prostatype Genomics AB’s PEG ratio is ―.

In the last 12 months, Prostatype Genomics AB had revenue of 199.00K and earned -41.05M in profits. Earnings per share was -13.67.

In the last 12 months, operating cash flow was -27.44M and capital expenditures 4.00, giving a free cash flow of -27.44M billion.

Prostatype Genomics AB pays an annual dividend of ―, resulting in a dividend yield of ―

Prostatype Genomics AB upcoming earnings date is May 22, 2025, TBA Not Confirmed.

Prostatype Genomics AB as a current ratio of 1.39, with Debt / Equity ratio of 0.00%

In the past 12 months, Prostatype Genomics AB has paid 0.00 in taxes.

Prostatype Genomics AB EV to EBITDA ratio is -0.64, with an EV/FCF ratio of -0.45.

Prostatype Genomics AB has kr11.69M in cash and marketable securities with kr666.42K in debt, giving a net cash position of -kr11.03M billion.

Gross margin is 963.82%, with operating margin of -20529.15%, and net profit margin of -20628.64%.

The average price target for Prostatype Genomics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―